When available, the Online Course format is included with the hard copy, eBook, or audio book formats!
Release Date: December 27, 2016
Expiration Date: December 31, 2019
Studies show that millions of people each year in the United States are affected by mental illness, however only about half of these receive treatment. Approximately 40 million people (18%) of the population suffer from an anxiety disorder annually. The prevalence of bipolar disorders is projected to be at 2.6% of the adult population and 11.2% for 13 to 18 year olds. Depressive conditions are among the most frequently occurring mental health disorders in this country, 6.6% of adults aged 18 or older had a major depressive episode in 2014. The lifetime prevalence of schizophrenia is calculated to be about 1% of the population.
The National Center for Health Workforce Analysis estimates that the increase in supply of primary care physicians will fall short of the increased demand for primary care providers by 2025. Additionally, the NCHWA has estimated that the number of nurse practitioners providing primary care services will increase by 30% by the year 2020.
With the growing number of nurse practitioners entering the healthcare field as primary care providers, there is a demonstrated need for education on the ever-increasing number of new pharmaceutical agents available, to treat the wide spectrum of mental illness. This course addresses these needs by providing up-to-date information and a variety of case studies to illustrate practical application of the learning content.
This course should not be taken in conjunction with N1692 - Antidepressants, 2nd Edition, N1710 - Differentiating Antipsychotics: An Overview of Properties Impacting Drug Selection, or N1713 - Anxiolytics and Traditional Mood Stabilizers.
Kentucky APRNs - fuliflls pharmacology requirement
- Describe how neurons work, how they transmit information to each other, and the relevance of this information to psychotropic medications.
- Discuss the pathophysiology of depression and appropriate treatment options for a patient with depression.
- Identify the differences among antipsychotic medications and draft a therapeutic plan of care for a patient with schizophrenia.
- Discuss pharmacotherapy for the treatment of anxiety disorders, and describe the patient teaching needs related to anxiolytic medications.
- Explain the role of mood stabilizers in the management of bipolar disorders. Describe the safe and effective use of mood stabilizers in management of bipolar disorder, and describe the patient teaching needs related to medications for mood disorders.
Charles F. Caley, BS Pharm, PharmD, BCPP, is Clinical Professor of Pharmacy Practice at the University of Connecticut School of Pharmacy and is a board-certified psychiatric pharmacist providing clinical and education services at the Institute of Living in Hartford, Connecticut. He received his BS in Pharmacy and PharmD degrees from the University of Rhode Island College of Pharmacy and then completed a 2-year specialty residency in psychiatric pharmacy at the Institute of Mental Health in Cranston, Rhode Island, and at Eastern State Hospital in Medical Lake, Washington. Dr. Caley is also an active provider of professional service to the psychiatric pharmacy profession. He is a founding member of the College of Psychiatric and Neurologic Pharmacists (CPNP) and served as the organization’s president in 2005-2006. Currently he is the Past President of the Board of Directors for the CPNP Foundation. Dr. Caley actively generates scholarship centered on psychotropic medications, and he has published in journals of pharmacy, psychiatry, and college health. In addition, he provides professional education presentations to audiences at the local, regional, and national level. Currently, Dr. Caley is working with others to transform the practice of pharmacy in Connecticut by being an active provider of comprehensive medication management services and also by leading a national effort to formally organize and recognize the practice efforts of those pharmacists in community mental health pharmacy settings.
Corey E. Scheer, RPh, BS Pharm, PharmD, BCPP, completed her BS Pharm and Doctor of Pharmacy degree at the University of Connecticut and then went on to complete a postgraduate year 1 residency at the University of Rochester Medical Center in Rochester, New York. From there, she completed a postgraduate year 2 residency specializing in psychiatric pharmacy at the Tuscaloosa VA Medical Center in Tuscaloosa, Alabama. After completing 2 years of residency, Dr. Scheer accepted a position as Clinical Assistant Professor of Pharmacy Practice at Western New England University College of Pharmacy, where she teaches psychiatry therapeutics and a case-based laboratory course, in addition to acting as a preceptor for final-year Doctor of Pharmacy students on clinical rotations at her practice site, Providence Behavioral Health Hospital. She is a board-certified psychiatric pharmacist. She has been teaching in the Doctor of Pharmacy program for 3 years.
- Courses must be completed on or before the expiration date noted in the course description above.
- You must score 75% or higher on the final exam and complete the course evaluation to pass this course and receive a certificate of completion.
- Through our review processes, Western Schools ensures that this course content is presented in a balanced, unbiased manner and is free from commercial influence. It is Western Schools’ policy not to accept commercial support.
- All persons involved in the planning and development of this course have disclosed no relevant financial relationships or other conflicts of interest related to the course content.